SSX2 and synovial sarcoma: Our work has identified the proto-oncogene FYN as a direct target of SS18-SSX and shown that suppression of SS18-SSX by a potent HDAC inhibitor (FK228) increases FYN expression levels, which may in turn reduces the treatment response of synovial sarcoma cells.